

Certificate of Analysis

Cell count	2 million per vial
Viability	95%
CD4+	99.4%
CD4+CD25+	91.9%
CD25+CD127-	79.7%
% Suppression at 1:8 Treg:Effector Ratio	66 %
Sterility Testing	Negative for bacteria, and fungi

Donor Information





Donor ID	363
Sex	Female
Age	68
Race	Caucasian
Height	5'5"
Weight	128 lbs
ABO Type	O positive

HLA typing

	Allele 1	Allele 2
HLA-A	0201	2402
HLA-B	15	35
HLA-C	03	04
HLA-DRB1	0103	0103


Donors are tested for the blood borne pathogens HIV-1 and 2, Hepatitis B, Hepatitis C and HTLV-1 and are negative. Cells should still be handled as if potentially infectious following biosafety level 2 procedures

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE



FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE

Suppression of anti-CD3-Mediated T Cell Proliferation by Culture Tregs Lot. 3959JN18



Co-Culture of Tregs Resulted in Suppression of Anti-CD3-mediated CD8+ T Cell Proliferation of Allogeneic Peripheral Blood Mononuclear Cells (PBMCs). In short, in a 96 well plate, 250,000 CFSE-labelled allogeneic responder PBMC were plated/well in the presence of 0.2 µg/mL anti-CD3 and varying number of Tregs as shown in the chart above. The plate was incubated in a 37 deg C, 6% CO2 incubator. After 6 days of culture, individual wells were harvested and labelled with PE-Cy5-labelled anti-CD8 mAb. Data was acquired on a flow cytometer and the extent of proliferation (Percent Divided, PD) was analyzed using FCS Express 4.0. % Suppression = 100- (PD in the presence of Treg/PD in the absence of Treg) x 100.